Some of the short-term benefits of an additional booster dose of the mRNA vaccine for health

The WHO states that there is an additional booster dose of the mRNA COVID-19 vaccine for the high-risk group, health workers, those over 60 years of age or immunocompromising conditions. As a general rule, an interval of 4-6 months after the completion of the initial series of vaccines may be considered for the first booster, especially in the case of Omicron, the World Health Organization says. Working group.

The WHO states that when considering additional booster doses, the two main conditions to evaluate are the use of additional booster doses for those who are not able to mount and maintain adequate immune response and should be considered for administering additional booster doses for higher protection. To maintain the health system during periods of risky population and periodic growth of health workers.

It states that the data available for WHO EUL COVID-19 vaccine products indicate that vaccine efficacy and immunogenicity are lower in immunocompromised individuals (ICPs) than in immunocompromised individuals. Given the significant risk of serious COVID-19 for ICP ICPs, if infected, the WHO has already introduced an extended initial series (i.e. third dose) for all COVID-19 ICPs as well as a booster dose (i.e. fourth dose). Has issued a recommendation. The vaccine, “he says.

The WHO noted that some countries are currently offering additional booster doses in addition to the first booster dose, adding that information regarding additional booster doses until May 2022 only exists for the mRNA vaccine, not for other vaccine platforms. The WHO cited seven studies. , Was conducted at a time when Omicron was the leading performing strain worldwide, evaluating the relative effectiveness of the fourth dose four months after the third dose of the mRNA vaccine compared to the three-dose recipients.

“Taken together, these studies show some short-term benefits of additional booster doses of the mRNA vaccine to health workers, those over 60 years of age or with immunocompromising conditions,” the WHO said. It says data to support additional doses for healthy young populations is limited; Preliminary data indicate that the benefit is minimal for young people.

“Limited data suggests that for the high-risk groups, there is a facility that supports additional booster dose administration,” the WHO said, among those at risk of serious illness or death (i.e. adults over 60 years of age, or those with a full immune system). (Not capable of mounting), the additional benefit of an additional booster dose of the mRNA vaccine may be “required”.

While it is said that the seasonality for SARS-COV-2 has not yet been fully established, evidence from the last two years supports the notion of a more significant transmission during the winter season. Seasonality should be considered for catch-ups and campaigns for high-risk individuals to improve early series coverage, ”the WHO added.